Medtronic has completed its acquisition of Israeli imaging analysis software developer CathWorks for $585 million with potential additional earn-out payments.
Under terms of the deal, Medtronic acquires CathWorks' FFRangio System, an AI-based platform that provides physiological assessment of the coronary tree from drug-free, wire-free coronary CT angiography (CCTA) exams, the company said. The system differs from traditional wire-based fractional flow reserve (FFR) assessment, which requires pressure wires, pharmacologic hyperemia, and measurements limited to a single transducer location.
The acquisition follows a 2022 strategic partnership and co-promotion agreement for the FFRangio System in the U.S., Europe, and Japan, and expands Medtronic's interventional cardiology portfolio, according to the firm.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
